Modelling and optimizing combination therapeutic strategies for KRAS- and EGFR-mutant lung cancer

Non-small cell lung carcinoma (NSCLC) is well-known for its high incidence (about 80% of lung cancer) and genetic heterogeneity. Personalized driver mutations such as EGFR and KRAS have established targeted therapies with kinase inhibitors, whereas immune checkpoint inhibitors (ICIs) have revolution...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of bioinformatics and computational biology Ročník 23; číslo 5; s. 2550017
Hlavní autoři:	Wu, Lanqi, Yu, Ruocheng, Yao, Minghui, Rahaman, Md Matiur, Fang, Zhaoyuan
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Singapore 01.10.2025
Témata:	Animals Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Humans Immune Checkpoint Inhibitors - therapeutic use Lung Neoplasms - drug therapy Lung Neoplasms - genetics Mice Mutation Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins p21(ras) - antagonists & inhibitors Proto-Oncogene Proteins p21(ras) - genetics combined therapy targeted therapy Lung cancer Boolean networks immunotherapy
ISSN:	1757-6334, 1757-6334
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!